TY - T1的疗效和安全性的伐地那非的男性勃起功能障碍引起的脊髓损伤JF -神经学乔-神经病学SP - 210 LP - 216 - 10.1212/01. wnl.0000194260.43583.32六世- 66 - 2非盟-首页 f·朱利亚诺盟- e . Rubio-Aurioles AU - m .肯内利AU - f . Montorsi AU - e·d·金盟-有请a . e . Finkbeiner AU - p . j . Pommerville AU - m . w . Colopy AU - h·j·威尔金斯盟b h·瓦希A2 - Y1 - 2006/01/24 UR - //www.ez-admanager.com/content/66/2/210.abstract N2 -目的:评估伐地那非的疗效和耐受性的男性勃起功能障碍(ED)由于创伤性脊髓损伤(SCI)。方法:多中心、双盲、安慰剂对照,与这些相应平行的组织为期12周的研究中,418名18岁或以上的男性ED超过6个月的SCI被随机分配到伐地那非(n = 207)或安慰剂(n = 211)(10毫克4周,然后维护或滴定在周4和5到20毫克8)。疗效评估包括勃起功能(EF)域国际勃起功能指数问卷的得分和日记问题渗透,维护安装完成性交,射精。结果:患者基线特征相似的伐地那非(平均年龄40岁)和安慰剂(平均年龄39岁)组。意思是基线EF域伐地那非组的得分分别为11.6和12.1(温和ED)在安慰剂组。EF domain score in the vardenafil group improved to 22.0 (mild ED) at last observation carried forward vs 13.5 in the placebo group (p < 0.001). Over 12 weeks of treatment, mean per-patient penetration (76% vs 41%), maintenance (59% vs 22%), and ejaculation (19% vs 10%) success rates were significantly greater vs placebo (all p < 0.001). The most frequently reported drug-related adverse events were headache (vardenafil 15%, placebo 4%), flushing (vardenafil 6%, placebo 0%), nasal congestion (vardenafil 5%, placebo 0%), and dyspepsia (vardenafil 4%, placebo 0%). Conclusion: Vardenafil significantly improved erectile and ejaculatory function and was generally well tolerated in men with erectile dysfunction due to spinal cord injury. ER -